Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story
Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.
This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.
New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.
It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.
Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.
These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.
Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.
This is the main counterweight: the company is still far from profitable, which limits near-term upside.